Malignant glioma: genetics and biology of a grave matter.
By E. Maher, F. Furnari, R. Bachoo, D. Rowitch, D. Louis, W. Cavenee, R. DePinho. Genes & Development, 2001
1,284 citations recorded by the source corpus.
Malignant brain tumors strike deep into the psyche of those receiving and those delivering the diagnosis. Malignant gliomas, the most common subtype of primary brain tumors, are aggressive, highly invasive, and neurologically destructive tumors considered to be among the deadliest of human cancers. In its most aggressive manifestation, glioblastoma (GBM), median survival ranges from 9 to 12 months, despite maximum treatment efforts—a statistical fact that has changed little over several decades of technological advances in neurosurgery, radiation therapy, and clinical trials of conventional and novel therapeutics. Over the same time period, there has been an explosion of knowledge in cancer biology and basic science discovery that has fueled meaningful progress in the treatment of many common human cancers, including those of the breast, lung, and prostate. It is perplexing that therapies used effectively in the treatment of these solid tumors are overwhelmingly ineffective in the treatment of GBM, perhaps reflecting the eccentric biology and cellular origin of this neoplasm. To date, only one new agent has been documented to have modest activity against intermediate-grade gliomas, whereas no effective agents have emerged for the treatment of GBM, despite 20 years of enrolling patients in clinical trials. It is ironic that although a comprehensive view of the genetic lesions encountered in malignant gliomas has been compiled, substantive conceptual and practical barriers remain in assigning functional significance to these genetic changes and in harnessing this basic information into the development of drugs that make a difference in patient care. The history of treating malignant gliomas dates back to the middle of the 19th century and parallels landmark advances in modern surgical technique and the clinical discipline of neurology. The first brain tumor surgery of the modern era was performed in 1884 by Rickman
Subfields: Cell Biology, Genetics, Oncology
View Paper: https://www.semanticscholar.org/paper/cc1833192c251f94dcf42824d56facea1975d3d6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Oncology
Citations in the corpus
- Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. (2006, background): “Intracranial tumors generated by 0308-NBE and 1228-NBE cells demonstrated extensive infiltration into the surrounding cerebral cortex, a pathognomonic feature of human GBMs (Galli et al., 2004; Maher et al., 2001; Sanai et al., 2005; Singh et al., 2004).”
- Cyclopamine‐Mediated Hedgehog Pathway Inhibition Depletes Stem‐Like Cancer Cells in Glioblastoma (2007, background): “Glioblastoma multiforme (GBM) are incurable brain cancers that exhibit various degrees of astrocytic differentiation [1, 2 ]. It has recently been proposed that GBM derive from neural stem or progenitor cells and that signaling pathways that play a key role in such primitive neural cells may also b”
- Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment (2017, background): “(Holland., 2000; Maher et al., 2001; Schwartzbaum et al., 2006; Agnihotri et al., 2013).”
- Cannabinoids: potential anticancer agents (2003, background): “As a consequence, survival after diagnosis is normally just 6–8 month”